Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2014

Open Access 01-12-2014 | Research

The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis

Authors: Qiliu Peng, Yu Lu, Xianjun Lao, Zhiping Chen, Ruolin Li, Jingzhe Sui, Xue Qin, Shan Li

Published in: Diagnostic Pathology | Issue 1/2014

Login to get access

Abstract

Background

NAD(P)H: quinone oxidoreductase 1 (NQO1) plays a central role in catalyzing the two-electron reduction of quinoid compounds into hydroquinones. The NQO1 Pro187Ser polymorphism was found to correlate with a lower enzymatic activity, which may result in increased incidence of carcinomas including breast cancer. Previous studies investigating the association between NQO1 Pro187Ser polymorphism and breast cancer risk showed inconsistent results. We performed a meta-analysis to summarize the possible association.

Methods

All studies published from January 1966 to February 2014 on the association between NQO1 Pro187Ser polymorphism and breast cancer risk were identified by searching electronic databases PubMed, EMBASE, Cochrane library, and Chinese Biomedical Literature database (CBM). The association between NQO1 Pro187Ser polymorphism and breast cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs).

Results

Ten studies with 2,773 cases and 4,076 controls were finally included in the meta-analysis. We did not observe a significant association between NQO1 Pro187Ser polymorphism and breast cancer risk when all studies were pooled into the meta-analysis. In subgroup analysis by ethnicity, significant increased breast cancer risk was found in Caucasians (Ser/Pro vs. Pro/Pro: OR = 1.145, 95% CI = 1.008–1.301, P = 0.038; Ser/Ser + Ser/Pro vs. Pro/Pro: OR = 1.177, 95% CI = 1.041–1.331, P = 0.009). When stratified by source of control, significant increased breast cancer risk was found in population-based studies (Ser/Pro vs. Pro/Pro: OR = 1.180, 95% CI = 1.035–1.344, P = 0.013; Ser/Ser + Ser/Pro vs. Pro/Pro: OR = 1.191, 95% CI = 1.050–1.350, P = 0.007). However, in subgroup analyses according to menopausal status, quality score, and HWE in controls, no any significant association was detected.

Conclusions

Our meta-analysis provides the evidence that the NQO1 Pro187Ser polymorphism contributed to the breast cancer susceptibility among Caucasians. Further large and well-designed studies are needed to confirm this association.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1248639991252504​
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.PubMedCrossRef
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.PubMedCrossRef
3.
Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ, Calle EE: Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16: 1784-1794. 10.1158/1055-9965.EPI-07-0247.PubMedCrossRef
4.
Ambrosone CB: Oxidants and antioxidants in breast cancer. Antioxid Redox Signal. 2000, 2: 903-917. 10.1089/ars.2000.2.4-903.PubMedCrossRef
5.
Schlager JJ, Powis G: Cytosolic NAD(P)H: (quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990, 45: 403-409. 10.1002/ijc.2910450304.PubMedCrossRef
6.
Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D: NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol. 2004, 65: 1238-1247. 10.1124/mol.65.5.1238.PubMedCrossRef
7.
Winski SL, Koutalos Y, Bentley DL, Ross D: Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res. 2002, 62: 1420-1424.PubMed
8.
Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH: Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 1995, 5: 199-206. 10.1097/00008571-199508000-00003.PubMedCrossRef
9.
Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D: Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997, 75: 69-75. 10.1038/bjc.1997.11.PubMedPubMedCentralCrossRef
10.
Siegel D, McGuinness SM, Winski SL, Ross D: Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999, 9: 113-121. 10.1097/00008571-199902000-00015.PubMedCrossRef
11.
Moran JL, Siegel D, Ross D: A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci U S A. 1999, 96: 8150-8155. 10.1073/pnas.96.14.8150.PubMedPubMedCentralCrossRef
12.
Ross D, Siegel D: NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004, 382: 115-144.PubMedCrossRef
13.
Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM: Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 1995, 72: 555-561. 10.1038/bjc.1995.373.PubMedPubMedCentralCrossRef
14.
Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R, Adamek J, Roth Z, Soucek P: Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet. 2004, 12: 848-854. 10.1038/sj.ejhg.5201249.PubMedCrossRef
15.
Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grunewald K, Haun M, Kraft HG: Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer. 2004, 90: 1989-1994. 10.1038/sj.bjc.6601779.PubMedPubMedCentralCrossRef
16.
Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP: Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers. 2011, 15: 343-349. 10.1089/gtmb.2010.0197.PubMedCrossRef
17.
Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, Li D: Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat. 2011, 125: 467-472. 10.1007/s10549-010-0966-0.PubMedCrossRef
18.
Yao S, Xu H, Chen Y, Shen X, Ju X, Wu W, Huang H, Dai L: Relationship between genetic polymorphisms of quinone oxidoreductase 1 and susceptibility and chemosensitivity of breast cancer. Chin J Exp Surg. 2013, 125: 684-687.
19.
Lajin B, Alhaj Sakur A, Alachkar A:Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women. Breast Cancer Res Treat. 2013, 138: 611-619. 10.1007/s10549-013-2467-4.PubMedCrossRef
20.
Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, Thompson J, Hall I, Kaufman J, Leung TF, Helms PJ, Hakonarson H, Halpi E, Navon R, Attia J: Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol. 2005, 162: 201-211. 10.1093/aje/kwi184.PubMedCrossRef
21.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.PubMedCrossRef
22.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22: 719-748.PubMed
23.
Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, Zheng W: Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1308-1315.PubMed
24.
Siegelmann-Danieli N, Buetow KH: Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology. 2002, 62: 39-45. 10.1159/000048245.PubMedCrossRef
25.
Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagami Y, Ogura M, Ando M, Sugimura Y, Tajima K: NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol. 2002, 7: 103-108.PubMed
26.
Aston CE, Ralph DA, Lalo DP, Manjeshwar S, Gramling BA, DeFreese DC, West AD, Branam DE, Thompson LF, Craft MA, Mitchell DS, Shimasaki CD, Mulvihill JJ, Jupe ER: Oligogenic combinations associated with breast cancer risk in women under 53 years of age. Hum Genet. 2005, 116: 208-221. 10.1007/s00439-004-1206-7.PubMedCrossRef
27.
Ma L, Zhao J, Li T, He Y, Wang J, Xie L, Qin X, Li S: Association between Tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol. 2014, 9: 74-10.1186/1746-1596-9-74.PubMedPubMedCentralCrossRef
28.
Wang Z, Zhang Y, Kong X, Li S, Hu Y, Wang R, Li Y, Lu C, Lin N, Chen W: Association of a polymorphism in PON-1 gene with steroid-induced osteonecrosis of femoral head in Chinese Han population. Diagn Pathol. 2013, 8: 186-10.1186/1746-1596-8-186.PubMedPubMedCentralCrossRef
29.
Dou K, Xu Q, Han X: The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis. Diagn Pathol. 2013, 8: 112-10.1186/1746-1596-8-112.PubMedPubMedCentralCrossRef
30.
Siegel D, Yan C, Ross D: NAD(P)H: quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012, 83: 1033-1040. 10.1016/j.bcp.2011.12.017.PubMedPubMedCentralCrossRef
31.
Dinkova-Kostova AT, Talalay P: NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys. 2010, 501: 116-123. 10.1016/j.abb.2010.03.019.PubMedPubMedCentralCrossRef
32.
Yu L, Chen J: Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: an update meta-analysis based on 51 research studies. Diagn Pathol. 2012, 7: 171-10.1186/1746-1596-7-171.PubMedPubMedCentralCrossRef
33.
Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA: NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol. 2008, 168: 1221-1232.PubMedPubMedCentralCrossRef
34.
Zhang Y, Liu L, Tang Y, Chen C, Wang Q, Xu J, Yang C, Miao X, Wei S, Chen J, Nie S: Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case–control study. Mol Biol Rep. 2012, 39: 9661-9668. 10.1007/s11033-012-1831-5.PubMedCrossRef
35.
Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M: NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006, 15: 979-987. 10.1158/1055-9965.EPI-05-0899.PubMedCrossRef
36.
Lou Y, Li R, Xiong L, Gu A, Shi C, Chu T, Zhang X, Gu P, Zhong H, Wen S, Han B: NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2013, 34: 3967-3979. 10.1007/s13277-013-0985-7.PubMedCrossRef
37.
Liu K, Tian H, Yu KZ, Shen WY, Mao ZC, Jin CH, Pan HB, He JX: Association between NQO1 Pro187Ser polymorphism and esophageal cancer: a meta-analysis. Tumour Biol. 2013, 35: 2063-2068.PubMedCrossRef
38.
Liu F, Luo L, Wei Y, Wang W, Li B, Yan L, Wen T: A functional NQO1 609C > T polymorphism and risk of hepatocellular carcinoma in a Chinese population. Tumour Biol. 2013, 34: 47-53. 10.1007/s13277-012-0509-x.PubMedCrossRef
39.
Danson S, Ward TH, Butler J, Ranson M: DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev. 2004, 30: 437-449. 10.1016/j.ctrv.2004.01.002.PubMedCrossRef
40.
Ioannidis JP, Patsopoulos NA, Evangelou E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007, 335: 914-916. 10.1136/bmj.39343.408449.80.PubMedPubMedCentralCrossRef
41.
Xu Z, Yu L, Zhang X: Association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis based on 22,475 subjects. Diagn Pathol. 2013, 8: 144-10.1186/1746-1596-8-144.PubMedPubMedCentralCrossRef
Metadata
Title
The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis
Authors
Qiliu Peng
Yu Lu
Xianjun Lao
Zhiping Chen
Ruolin Li
Jingzhe Sui
Xue Qin
Shan Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-9-100

Other articles of this Issue 1/2014

Diagnostic Pathology 1/2014 Go to the issue

Research

RETRACTED ARTICLE: Dysregulation of cell cycle related genes and microRNAs distinguish the low- from high-risk of prostate cancer

Research

Tea consumption didn’t modify the risk of fracture: a dose–response meta-analysis of observational studies

Research

RETRACTED ARTICLE: Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia

Research

Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations

Editorial

Diagnostic pathology in 2013: facts, thoughts, and perspectives

Research

Unveiling transcription factor regulation and differential co-expression genes in Duchenne muscular dystrophy